A phase III study on patients with platinum-sensitive recurrent ovarian cancer taking PARP inhibitors as maintenance therapy found that these patients had longer progression-free survival compared with the placebo group, independent of the BRCA1/2 mutation status or other HR repair gene status (7). Here, PARP1 is linked to ovarian cancer.